Visual and Refractive Outcomes of a New Hydrophobic Trifocal Toric Intraocular Lens

Abstract

Purpose

To evaluate the visual outcomes and efficacy of astigmatism correction using a new hydrophobic trifocal toric intraocular lens (IOL).

Methods

This study involved 62 eyes implanted with the FineVision HP Toric IOL. The visual and refractive outcomes were assessed preoperatively and 6 weeks after the surgery. Specifically, monocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA) at 80 and 60 cm and uncorrected near visual acuity at (UNVA) at 40 cm were evaluated. The rotational stability of the lens was also assessed.

Results

Sixty-one eyes (98.39%) were within ±1.00D and 55 eyes (88.71%) were within ±0.50 D of spherical equivalent, with a mean value of 0.09±0.39 D. 51 (82.26%) and 61 (98.39%) eyes had a UDVA of ≥20/20 and ≥20/25, respectively, and for CDVA these values were as follows: 59 (95.16%) and 62 eyes (100%), respectively. The mean UDVA and CDVA were 0.01±0.06 and −0.01±0.04logMAR, respectively. Greater than or equal to unaided 20/20 vision was achieved at 40 cm in 42 (67.74%), UIVA at 60 cm in 42 (67.74%) and 50 eyes (80.65%) at 80 cm. Those achieving ≥20/25 were 56 (90.32%, 40 cm), 59 (95.16%, 60 cm), and 62 eyes (100%, 80 cm). Postoperative mean values were 0.04±0.07, 0.03±0.07, and 0.00±0.07logMAR for UCNVA, UIVA at 60 cm, and UIVA at 80 cm, respectively. The mean rotation of the IOL was 5.8 degrees.

Conclusion

This hydrophobic trifocal toric IOL provides good refractive outcomes with excellent visual acuity across multiple distances, providing a full range of focus.

Keywords:

• astigmatism
• trifocal
• toric
• multifocal
• cataract

Data Sharing Statement

Data not available for sharing.

Disclosure

Sheraz Daya reports grant support from Allotex and Johnson & Johnson Vision; consultant/advisor of, lecture fees, and grant support from Bausch + Lomb; consultant/advisor of and lecture fees from BVI – Physiol; consultant/advisor of Cristalens, Carl Zeiss Meditec, Nidek, Inc., Oyster Point, Tarsus, and Vialase; consultant/advisor of, stock options, grant support from Excellens; owner of company of Infinite Medical Ventures (EO); consultant/advisor for and stock options from PRN. The authors report no other conflicts of interest in this work.